Lataa...

Pharmacodynamic Separation of Gemcitabine and Erlotinib in Locally Advanced or Metastatic Pancreatic Cancer: Therapeutic and Biomarker Results

PURPOSE: Erlotinib marginally improves survival when administered continuously with gemcitabine to patients with advanced pancreatic cancer; however, preclinical data suggest that there is antagonism between chemotherapy and Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors when the...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Int J Clin Oncol
Päätekijät: Semrad, Thomas, Barzi, Afsaneh, Lenz, Heinz-Josef, Hutchins, Irene M., Kim, Edward J., Gong, I-Yeh, Tanaka, Michael, Beckett, Laurel, Holland, William, Burich, Rebekah A., Snyder-Solis, Leslie, Mack, Philip, Lara, Primo N.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2014
Aiheet:
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4318776/
https://ncbi.nlm.nih.gov/pubmed/25091263
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10147-014-0730-2
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!